Yvonne L. Greenstreet, M.D., is the Chief Executive Officer and principal executive officer at Alnylam Pharmaceuticals Inc., a leading biopharmaceutical company focused on the discovery, development, and commercialization of RNAi therapeutics. Dr. Greenstreet joined Alnylam in 2016 as the Chief Operating Officer before being appointed CEO in 2021. With a strong background in medicine and extensive experience in the pharmaceutical industry, she has played a pivotal role in steering the company towards significant growth and success. Prior to joining Alnylam, Dr. Greenstreet held several key leadership positions in the pharmaceutical sector. She served as the President of Pfizer's Established Products Business Unit, where she was responsible for a portfolio of over 150 products across more than 70 markets. Before that, she was the Senior Vice President and Head of Specialty Care and Oncology at Pfizer, overseeing the development and commercialization of treatments for various diseases. Dr. Greenstreet's strategic vision and operational expertise have been instrumental in driving Alnylam's mission to transform the lives of patients suffering from rare and debilitating diseases through innovative RNAi therapies. As CEO of Alnylam, Dr. Greenstreet has led the company through a period of remarkable progress, including the successful launch of multiple groundbreaking therapies and the expansion of the company's global footprint. Under her leadership, Alnylam has continued to advance its pipeline of RNAi therapeutics, securing approvals for treatments such as ONPATTRO, GIVLAARI, and OXLUMO, which address previously unmet medical needs. Dr. Greenstreet's commitment to scientific excellence, patient-centricity, and operational efficiency has solidified Alnylam's position as a pioneer in the field of genetic medicine, and she remains dedicated to realizing the full potential of RNAi technology to improve patient outcomes worldwide.